使用氟硫酸弹头对野生型HIV-1逆转录酶进行共价抑制。
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
作者信息
Ippolito Joseph A, Niu Haichan, Bertoletti Nicole, Carter Zachary J, Jin Shengyan, Spasov Krasimir A, Cisneros José A, Valhondo Margarita, Cutrona Kara J, Anderson Karen S, Jorgensen William L
机构信息
Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.
出版信息
ACS Med Chem Lett. 2021 Jan 6;12(2):249-255. doi: 10.1021/acsmedchemlett.0c00612. eCollection 2021 Feb 11.
Abstract
Covalent inhibitors of wild-type HIV-1 reverse transcriptase (CRTIs) are reported. Three compounds derived from catechol diether non-nucleoside inhibitors (NNRTIs) with addition of a fluorosulfate warhead are demonstrated to covalently modify Tyr181 of HIV-RT. X-ray crystal structures for complexes of the CRTIs with the enzyme are provided, which fully demonstrate the covalent attachment, and confirmation is provided by appropriate mass shifts in ESI-TOF mass spectra. The three CRTIs and six noncovalent analogues are found to be potent inhibitors with both IC values for in vitro inhibition of WT RT and EC values for cytopathic protection of HIV-1-infected human T-cells in the 5-320 nM range.
摘要
有报道称发现了野生型HIV-1逆转录酶的共价抑制剂（CRTIs）。三种源自儿茶酚二醚非核苷抑制剂（NNRTIs）并添加了氟硫酸弹头的化合物被证明可共价修饰HIV-RT的Tyr181。提供了CRTIs与该酶复合物的X射线晶体结构，充分证明了共价结合，并且电喷雾飞行时间质谱（ESI-TOF）中的适当质量位移也证实了这一点。发现这三种CRTIs和六种非共价类似物都是强效抑制剂，其对野生型逆转录酶的体外抑制IC值以及对HIV-1感染的人类T细胞的细胞病变保护EC值均在5-320 nM范围内。
相似文献
1
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
ACS Med Chem Lett. 2021 Jan 6;12(2):249-255. doi: 10.1021/acsmedchemlett.0c00612. eCollection 2021 Feb 11.
2
Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study.
Int J Mol Sci. 2023 Jan 7;24(2):1215. doi: 10.3390/ijms24021215.
3
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
J Mol Biol. 1996 Dec 20;264(5):1085-100. doi: 10.1006/jmbi.1996.0698.
4
Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group.
J Am Chem Soc. 2013 Nov 6;135(44):16705-13. doi: 10.1021/ja408917n. Epub 2013 Oct 24.
5
Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.
Eur J Med Chem. 2023 Dec 15;262:115894. doi: 10.1016/j.ejmech.2023.115894. Epub 2023 Oct 20.
6
Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2023 Mar 15;84:129216. doi: 10.1016/j.bmcl.2023.129216. Epub 2023 Mar 3.
7
Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9725-9730. doi: 10.1073/pnas.1711463114. Epub 2017 Aug 21.
8
Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region.
Pharmaceuticals (Basel). 2022 Nov 19;15(11):1438. doi: 10.3390/ph15111438.
9
Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
J Med Chem. 2015 Mar 26;58(6):2737-45. doi: 10.1021/jm501908a. Epub 2015 Mar 5.
10
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
J Med Chem. 2005 Dec 1;48(24):7582-91. doi: 10.1021/jm0500323.
引用本文的文献
1
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2.
RSC Med Chem. 2025 Aug 1. doi: 10.1039/d5md00440c.
2
Advancing Covalent Ligand and Drug Discovery beyond Cysteine.
Chem Rev. 2025 Jul 23;125(14):6653-6684. doi: 10.1021/acs.chemrev.5c00001. Epub 2025 May 22.
3
Proximity-induced SuFEx increases the potency of cytosolic nucleotidase inhibitors and reveals a rare example of covalently targeted histidine.
RSC Chem Biol. 2025 Apr 23. doi: 10.1039/d5cb00005j.
4
Sulfur fluoride exchange.
Nat Rev Methods Primers. 2023;3. Epub 2023 Aug 3.
5
Bioinspired Pyrano[2,3-]chromen-8-ones: Ring C-Opened Analogues of Calanolide A: Synthesis and Anti-HIV-1 Evaluation.
Biomimetics (Basel). 2024 Jan 11;9(1):44. doi: 10.3390/biomimetics9010044.
6
Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
Viruses. 2023 Sep 25;15(10):1992. doi: 10.3390/v15101992.
7
Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.
Eur J Med Chem. 2023 Dec 15;262:115894. doi: 10.1016/j.ejmech.2023.115894. Epub 2023 Oct 20.
8
Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2023 Mar 15;84:129216. doi: 10.1016/j.bmcl.2023.129216. Epub 2023 Mar 3.
9
Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study.
Int J Mol Sci. 2023 Jan 7;24(2):1215. doi: 10.3390/ijms24021215.
10
Sulfur(VI) fluorides as tools in biomolecular and medicinal chemistry.
Org Biomol Chem. 2023 Feb 15;21(7):1356-1372. doi: 10.1039/d2ob01891h.
本文引用的文献
1
Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.
Cancer Cell. 2020 Jan 13;37(1):3-4. doi: 10.1016/j.ccell.2019.12.009.
2
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Expert Opin Drug Metab Toxicol. 2019 Oct;15(10):813-829. doi: 10.1080/17425255.2019.1673367. Epub 2019 Oct 17.
3
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017.
Lancet HIV. 2019 Dec;6(12):e831-e859. doi: 10.1016/S2352-3018(19)30196-1. Epub 2019 Aug 19.
4
Two-Drug Regimen for HIV.
JAMA. 2019 May 21;321(19):1862. doi: 10.1001/jama.2019.6188.
5
Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.
Antiviral Res. 2019 Jul;167:110-116. doi: 10.1016/j.antiviral.2019.04.010. Epub 2019 Apr 26.
6
Long-Acting HIV Drugs for Treatment and Prevention.
Annu Rev Med. 2019 Jan 27;70:137-150. doi: 10.1146/annurev-med-041217-013717. Epub 2018 Oct 24.
7
Emerging Utility of Fluorosulfate Chemical Probes.
ACS Med Chem Lett. 2018 Jun 27;9(7):584-586. doi: 10.1021/acsmedchemlett.8b00276. eCollection 2018 Jul 12.
8
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802-E811. doi: 10.1073/pnas.1717932115. Epub 2017 Dec 26.
9
Lysine-Targeting Covalent Inhibitors.
Angew Chem Int Ed Engl. 2017 Nov 27;56(48):15200-15209. doi: 10.1002/anie.201707630. Epub 2017 Oct 27.
10
Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9725-9730. doi: 10.1073/pnas.1711463114. Epub 2017 Aug 21.
Zotero 插件